The Rat Plasminogen System, Intrahepatic Fibrinolysis and Carbon Tetrachloride Hepatotoxicity

I Innerfield; G. R Rowley; P Zweil; J Porpora

doi:10.1055/s-0038-1655054

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1967; 18(03/04): 447-455
DOI: 10.1055/s-0038-1655054

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

The Rat Plasminogen System, Intrahepatic Fibrinolysis and Carbon Tetrachloride Hepatotoxicity

Authors

I Innerfield

¹Department of Biochemistry, Graduate and Dental Schools, Fairleigh Dickinson Univerity Teaneck, New Jersey and the Department of Pathology, Bergen Pines County Hospital, Paramus, New Jersey
G. R Rowley

¹Department of Biochemistry, Graduate and Dental Schools, Fairleigh Dickinson Univerity Teaneck, New Jersey and the Department of Pathology, Bergen Pines County Hospital, Paramus, New Jersey
P Zweil

¹Department of Biochemistry, Graduate and Dental Schools, Fairleigh Dickinson Univerity Teaneck, New Jersey and the Department of Pathology, Bergen Pines County Hospital, Paramus, New Jersey
J Porpora

¹Department of Biochemistry, Graduate and Dental Schools, Fairleigh Dickinson Univerity Teaneck, New Jersey and the Department of Pathology, Bergen Pines County Hospital, Paramus, New Jersey

Abstract

Summary

Carbon tetrachloride hepatotoxicity in rats is significantly reduced by small doses of orally given enzymes which activate the rat plasminogen system. Enzymes incapable of activating rat plasminogen are ineffective. The suggestion is made that the liver protection afforded by small doses of SK or trypsin relates to the pro-coagulant, permeability-decreasing, anti-edema action of suitably low doses of SK or trypsin.

Full Text

References

References
1 Innerfield I, Cohen H, Zweil P. Effect of orally administered proteolytic enzymes on carbon tetrachloride induced granuloma pouch. Proc. Soc. exp. Biol. (N. Y) 133: 871 1966;
2 Remmert L. F, Cohen P. P. Partial purification and properties of proteolytic enzymes of human serum. J. biol. Chem. 181: 431 1949;
3 Johnson A. J, Tse A. O. Fibrinolytic assay for plasmin, purified or in biological fluids. Blood coagulation, hemorrhage and thrombin. Ed. Tocantins L. M, Kazal L. A. 467-468 Greene and Stratton, Pub; New York, N.Y: 1964
4 Innerfield I, Hochberg R. Endogenous release of plasminogen activator from gastric juice by orally given streptokinase. Curr. ther. Res. 04: 524 1962;
5 Innerfield I, Shub H, Boyd L. J. Rucally Administered Streptokinase. Clinical and Experimental Observations. New Engl. J. Med. 258: 1069 1958;
6 Innerfield I. Oral enzyme therapy. Trans. N.Y. Acad. Sci. 28: 412 1966;
7 Innerfield I, Gimble F. S, Blincoe E. Peptidase activity in rat urine following orally given proteases. Life Sci. 02: 671 1963;
8 Innerfield I, Harvey R, Luongo F, Blincoe E. Urine peptidase activity following single and, multiple oral doses of streptokinase. Proc. Soc. exp. Biol. (N. Y) 116: 573 1964;
9 Innerfield I, Gimble F. S, Blincoe E. Tissue peptidase activity following orally given proteases. Life Sci. 03: 267 1964;
10 Innerfield I, Bundy R, Hochberg R. Bradykinin antagonism following oral protease therapy. Proc. Soc. exp. Biol. (N. Y) 112: 295 1963;
11 Innerfield I, Luongo F. Analgesic and anti-inflammatory affects of orally given streptokinase. Proc. Soc. exp. Biol. (N. Y) 113: 465 1963;
12 Innerfield I, Harvey R, Luongo F, Blincoe E. Inhibition of the generalized Shwartzman reaction in the pregnant golden hamster by oral streptokinase. Life Sci. 03: 673 1964;
13 Galton M. Presentation at meeting of Section of Biological and Medical Sciences. N.Y. Acad. Sci. December 7, 1965
14 Innerfield I, Cannavella L, Mezzatesta A, Hochberg R. Modification of kinin activity in injured tissue by oral kinases and proteases. Proc. Soc. exp. Biol. (N. Y) 112: 189 1963;
15 Innerfield I, Nussbaum M, Rowley G. R, Siew C, Zweil P, Bartos H. Effect of oral varidase on coagulation defects in hemophilia and cirrhosis. Life Sci. 14: 683 1965;
16 Innerfield I, Bigonzi R, Geiger R, Bonhag R, Darahjian R. The ‘‘fibrin to clot” clotting time after oral streptokinase or papain. Life Sci. 04: 1301 1965;
17 Innerfield I, Rowley G. R, Zweil P, Siew G. Urinary proteolytic activity following oral streptokinase. Enzym, biol. clin. 07: 149 1966;
18 Webster M. E, Innerfield I. Interrelationship of human plasma kallikrein and plasmin in inflammation. Enzym, biol. clin. 03: 129 1965;
19 Pollack P. J. Oral administration of enzymes from carica papaya: report of a double-blind clinical study. Curr. ther. Res. 04: 229 1962;
20 Logan B. D, King J. R. Proteolytic enzymes in ureteral edema; a laboratory study. Invest. Urol. 03: 17 1965;
21 Avakian S. Current concepts of therapy: Chymotrypsin and trypsin, New Engl. J. Med. 264: 764 1961;
22 Avakian S. Further studies on the absorption of chymotrypsin. Clin. Pharmacol. Ther. 05: 712 1964;
23 Bogner R. L, Edelman A, Martin G. J. In vivo observations with radioactive trypsin, Arch, intern. Pharmacodyn 118: 122 1959;
24 Brendel R, Beiler J. M, Martin G. S. Absorption of trypsin from the buccal pouch. Amer. J. Pharm. 128: 172 1956;
25 Golman R. W. Proteolytic enzymes in clinical medicine. Clin. Pharmacol. Ther. 06: 598 1965;
26 Innerfield I. G. Enzymes in clinical medicine. McGraw-Hill Book Company, Inc; New York: 1960
27 Kabacoff B. L, Umkey M, Wohlman A, Akavian S. Sensitive and reproducible method for chymotrypsin. J. Pharm. Sci. 52: 1188 1963;
28 Kabacoff B. L, Wahlman R, Umkay M, Avakain S. Absorption of chymotrypsin from the intestinal tract. Nature (Lond) 199: 815 1963;
29 Martin G. J, Bogner R. L, Edelman A. Further in vivo observations with radioactive trypsin. Amer. J. Pharm. 129: 386 1957;
30 Martin G. S. Clinical enzymology. Little, Brown & Company; Boston: 1958
31 Megel H, Strauµ R, Ho R, Beiler M. Detection of trypsinlike activity in the plasma of rats after oral administration of trypsin, Arch. Biochem. 108: 193 1964;
32 Miller J. M, Williard R. F, Polachek A. An investigation of trypsin I¹³¹ in patients. Exp. Med. Surg. 18: 352 1960;
33 Koller F. Importance of coagulation besides haemostasis. Acta haemat. (Basel) 36: 133 1966;
34 Albrechtsen O. K. The fibrinolytic activity of human tissues. Brit. J. Haemat. 03: 284 1957;
35 Astrup T, Rasmussen J, Amery A. Fibrinolytic activity of cirrhotic liver. Nature (Lond) 185: 619 1960;
36 Fletcher A. P, Biederman O, Moore D, Sherry S. Abnormal plasminogen-plasmin system activity in patients with hepatic cirrhosis. J. clin. Invest 43: 681 1964;
37 Fletcher A. P, Alkjaersig N, Sherry S. Fibrinolytic mechanisms and the development of thrombolytic therapy. Amer. J. Med. 33: 738 1962;
38 Cameron G. R, Karunarantne W. A. E. Carbon tetrachloride cirrhosis in relation to liver regeneration. J. Path. Bact. 42: 1 1936;
39 Martin G. J. Anti-inflammatory effect of trypsin. Ann. N.Y. Acad. Sci. 68: 70 1959;
40 Koller F. Peptides active in clotting and vascular function. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 20, Discussion 236 1966;
41 Copley A. L. The anti-bradykinin action of fibrinolysin and other studies on capillary permeability employing different mediators and synthetic bradykinin. Biochem. Pharmacol. 10: 67 1962;
42 Asheim E, Tsuluca V, Copely A. L. Quantitative relation between certain fibrinolysis factors and inflammation. Proc. Soc. exp. Biol. (N. Y) 112: 434 1963;
43 Innerfield I. Recent developments in clinical enzymology. Exp. Med. Surg., Suppl. 04: 36 1965;
44 Ambrus J. L, Lassman H. B, de Marchi J. J. Absorption of Exogenous and Endogenous Proteolytic Enzymes. Clin. Pharmacol. Ther. 08: 362 1967;